CITI/CALL/VERTEX PHARMACEUTICALS/320/0.1/16.01.25 | Market Closed - Deutsche Boerse AG 10:55:39 17/05/2024 pm IST | ||
| 12.81 EUR | +3.39% |
|
| Current month | +42.65% | ||
| 1 month | +40.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 12.81 | +3.39% |
| 16/24/16 | 12.39 | +0.41% |
| 15/24/15 | 12.34 | +9.98% |
| 14/24/14 | 11.22 | -3.19% |
| 13/24/13 | 11.59 | +5.94% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 10:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KH24X8 |
| ISIN | DE000KH24X87 |
| Date issued | 01/02/2023 |
| Strike | 320 $ |
| Maturity | 16/01/2025 (243 Days) |
| Parity | 10 : 1 |
| Emission price | 6.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.86 € |
|---|---|
| Lowest since issue | 4.15 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant
